The Association for Accessible Medicines’ report on Medicare Part D tiering revealed low coverage rates for insulin and adalimumab biosimilars across plans.
Despite the US having more biosimilar options than ever before, Medicare Part D plans still prefer reference insulin glargine (Lantus) and adalimumab (Humira) over lower-priced biosimilar alternatives, according to a report from the Association for Accessible Medicines (AAM).
The report looked at results from Avalere’s analysis on understanding the distribution of biosimilars relative to their originators on Medicare Part D formulary tiers for program year (PY) 2023. Avalere synthesized public use files (PUFs) from PY 2024 to assess coverage, tiering, and utilization management of drugs covered under Part D plans, including Medicare Advantage plans, focusing specifically on the insulin glargine, adalimumab, epoetin alfa, pegfilgrastim, and filgrastim markets.
Avalere included over 5500 plans across all 50 states and Washington, DC, and the 5 largest Part D parent organizations in 2023 (United Healthcare, Humana, CVS, Centene, Cigna), regardless of whether they covered any of the studied products.
By parent organization, the researchers looked at:
Results showed that Lantus generally had higher coverage, preferred tiering, and less restrictive utilization management (UM) compared with its biosimilars. While 80% of plans covered branded or unbranded Lantus, less than 10% of plans covered branded or unbranded insulin biosimilars. There were also no differences in coverage for prefilled pens vs prefilled syringes for coverage, tiering, or UM. United Healthcare, CVS, Centene, and Cigna did not cover any insulin biosimilars.
Similarly, immunological agent biosimilars were significantly less likely to be covered by plans compared with their reference products. When covered, immunological agent biosimilars were typically placed on specialty tiers, indicating a higher level of restriction or management compared with reference products.
Humira biosimilars were not covered, and prior authorization was required for Humira, suggesting that plans were more inclined to cover the reference product rather than its biosimilars. UM strategies like prior authorization were commonly applied to control access to Humira. However, CVS, Cigna, and Centene did not cover any adalimumab biosimilars despite 8 products entering the market by the end of July 2023.
Although some biosimilars, such as Cyltezo, were covered by a higher number of plans compared with other Humira biosimilars, overall coverage of Humira biosimilars remained low across all plans, likely because it was the first adalimumab biosimilar to be granted interchangeability status.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.